MoonLake Immunotherapeutics (MLTX) Investors are Reminded to Contact BFA Law Before the December 15 Securities Fraud Class Action DeadlineNovember 16, 2025 7:08 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 16, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securi ...

诉讼案件基本信息 - 罗森律师事务所鼓励在2024年3月10日至2025年9月29日期间购买MoonLake Immunotherapeutics普通股的投资者在2025年12月15日这一重要截止日期前确保获得法律代理 [1] - 投资者可能有权通过风险代理收费安排获得补偿，无需支付任何自付费用或成本 [2] 诉讼指控核心内容 - 指控称被告在整个集体诉讼期间就纳米抗体与单克隆抗体的区别做出虚假和/或误导性陈述，并且未能披露重要事实 [5] - 具体指控包括未披露SLK和BIMZELX具有相同的分子靶点，以及SLK的纳米抗体结构不会带来优于BIMZELX传统单克隆结构的临床益处 [5] - 指控还涉及SLK纳米抗体结构所谓的组织渗透性不会转化为临床疗效，以及基于上述情况，被告对其关于SLK优于单克隆抗体的正面陈述缺乏合理依据 [5] - 诉讼声称当真实细节进入市场后，投资者遭受了损失 [5] 律师事务所背景信息 - 罗森律师事务所专注于证券集体诉讼和股东衍生诉讼，其律师曾获得Lawdragon和Super Lawyers的认可 [4] - 该事务所曾达成针对中国公司的史上最大证券集体诉讼和解，并在2017年被ISS证券集体诉讼服务评为和解数量第一 [4] - 自2013年以来，该事务所每年排名前四，已为投资者追回数亿美元，其中2019年即为投资者获得超过4.38亿美元 [4]

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...

New York, New York--(Newsfile Corp. - November 14, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177495&wire=5&utm_campaign=23or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Can ...

[You may also click here for additional information] NEW YORK, Nov. 14, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake" or the "Company") (NASDAQ: MLTX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigati ...

Accessibility StatementSkip Navigation WHAT'S NEXT? If you suffered a loss in MoonLake during the relevant time frame, you have until December 15, 2025Â to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the pas ...

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA LawNovember 14, 2025 6:08 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 14, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 13 ...

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit. Investors have until December 15, 2025, to as ...

New York, New York--(Newsfile Corp. - November 12, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177026&wire=5&utm_campaign=14or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Can ...